Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Growth Disorder Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IGF2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IGF2 Recombinant Protein High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. Correct disulfide mapping. |
View IGF2 Products |
| Gene Delivery | IGF2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View IGF2 Products |
| Benchmark Ab | Anti-IGF2 (Sequence of Xentuzumab) Recombinant positive control antibody for ligand-neutralization assays. |
View IGF2 Products |
| Validator | IGF2 siRNA Set For target knockdown verification in functional cell assays. |
View IGF2 Products |
| Related Target A | IGF1 Homologous ligand sharing IGF-1R signaling pathway; critical for cross-reactivity screening. |
View IGF1 Products |
| Related Target B | IGF1R Primary signaling receptor mediating the oncogenic effects of IGF2. |
View IGF1R Products |
| Related Target C | INSR Insulin Receptor (Isoform A binds IGF2 with high affinity); essential for metabolic off-target safety screening. |
View INSR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-reactivity with Insulin / INSR | High-purity human INSR and Insulin proteins available to run counter-screening panels. |
| Distinguishing IGF1 vs. IGF2 binding | Highly purified recombinant IGF1 and IGF2 proteins with verified theoretical MW and native-like folding. |
| Lack of Controls | Clinical Benchmark Antibodies (Xentuzumab biosimilar) included |
| False Positives | Validated siRNA included for specificity checks |
Live IGF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IGF2 therapeutics is intensifying, with major players shifting focus from traditional IGF-1R monoclonal antibodies to ligand-neutralizing antibodies and bispecific traps. Because IGF-1R inhibitors historically suffered from severe toxicities (such as hyperglycemia due to growth hormone feedback loops and cross-reactivity with the insulin receptor), directly targeting the IGF2 ligand has emerged as a safer, highly selective alternative. As first-generation therapies reach the clinic, the next wave of R&D is targeting bispecific constructs and antibody-drug conjugates (ADCs) that exploit IGF2 overexpression in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Ligand-Neutralizing mAb | Boehringer Ingelheim, Pierre Fabre | Solid Tumors, Non-Small Cell Lung Cancer (NSCLC) | Ligand-binding competition assay (Requires high-purity, sequence-verified IGF2 recombinant protein) |
| Bispecific Antibodies / Traps | Roche, Academic Institutions | Colorectal Cancer, Breast Cancer | Dual target binding affinity testing (Need orthologous IGF1 and IGF2 proteins to confirm dual blocking) |
| siRNA / RNAi Therapeutics | Alnylam, Custom Developers | Hepatocellular Carcinoma (HCC) | In vitro knockdown confirmation (Requires sequence-verified IGF2 siRNA and Lentivirus for target validation) |